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Objectives: We conducted a cluster-randomized feasibility trial of 90-minute Chlamydia trachomatis tests
and same day on-site treatment (‘Test n Treat/TnT’) in six technical colleges in London, England, to assess
TnT uptake rates; follow-up rates; prevalence of C. trachomatis at baseline and 7 months; time to
treatment; acceptability of TnT.
Methods: Participants completed questionnaires and provided genitourinary samples at baseline and
7 months. Participants were informed that baseline samples would not be tested for 7 months and were
advised to get screened independently. Colleges were randomly allocated 1:1 to intervention (TnT) or
control (no TnT).
One month and 4 months post recruitment, participants at intervention colleges were texted invitations
for on-site free C. trachomatis tests. A purposive sample of students who did/did not attend for screening
were interviewed (n ¼ 26).
Results: Five hundred and nine sexually active students were recruited: median age 17.9 years, 47% male,
50% black ethnicity, 55% reporting two or more sexual partners in the previous year. TnT uptake was 13%
(33/259; 95% CI 8.9e17.4%) at 1 month and 10% (26/259; 6.7e14.4%) at 4 months with overall
C. trachomatis positivity 5.1% (3/59; 1.1e14.2%). Follow-up at 7 months was 62% (317/509) for ques-
tionnaires and 52% (264/509) for samples. C. trachomatis prevalence was 6.2% (31/503) at baseline and
6.1% (16/264) at 7 months. Median time from test to treatment was 15 h. Interviews suggested low test
uptake was associated with not feeling at risk, perceptions of stigma, and little knowledge of sexually
transmitted infections (STIs).
Conclusions: Despite high C. trachomatis rates at baseline and follow-up, uptake of testing was low. Like
many countries, England urgently needs better sex education, including making STI testing routine/
normal.
Trial registration ISRCTN58038795 P. Oakeshott, Clin Microbiol Infect 2019;25:865
© 2019 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and
Infectious Diseases. This is an open access article under the CC BY license (http://creativecommons.org/
licenses/by/4.0/).Health Research Institute, St
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es/by/4.0/).Introduction
Chlamydia trachomatis is a common, often asymptomatic, bac-
terial sexually transmitted infection (STI) which can lead to pelvicof Clinical Microbiology and Infectious Diseases. This is an open access article under
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may be associated with adverse pregnancy outcomes [3]. However,
uptake of C. trachomatis testing by 16e24 year olds in many
countries is too low to reduce infection rates [1,4e8], and there are
often delays in treatment. Bringing novel 90-minute C. trachomatis
tests [9,10] and same day on-site treatment (‘TnT ¼ Test n Treat’) to
the community might get more young people treated faster [6,10].
This could reduce rates of infection, onward transmission and
adverse reproductive health effects, and save healthcare costs
[7,11].
In order to address a number of unknown parameters required
for the design of a future deﬁnitive study, we conducted a cluster
randomized feasibility trial (or pilot study) of frequent, rapid TnT in
six technical (‘Further Education’/FE) colleges in London, England,
over the academic year 2016e17. (FE colleges offer both academic
and practical courses such as plumbing and hairdressing, and take
many students from socio-economically deprived backgrounds.
C. trachomatis positivity may be 6e8% [12e14].)
We assessed the following feasibility outcomes:
 recruitment rates
 TnT uptake rates
 follow-up rates
 prevalence of C. trachomatis at baseline and 7 months
 time to treatment
 acceptability of TnT.
We selected a cluster design for practical reasons for delivering
screening, which would reﬂect the design of a deﬁnitive trial. This
was a feasibility study and was not powered to assess the effec-
tiveness of TnT. Although we used a combined C. trachomatis/
Neisseria gonorrhoeae rapid test (Cepheid CT/NG GeneXpert® sys-
tem [9]), on-site treatment (TnT) was for individuals with
C. trachomatis only [15] as participants with N. gonorrhoeae (or
C. trachomatis/N. gonorrhoeae dual infection) were referred to a
sexual health clinic. Detailed qualitative and economic analyses will
be presented elsewhere.
Methods
Recruitment and baseline samples
All technical colleges/clusters were eligible and all six
approached agreed to participate. As previously described [15],
researchers recruited students from public areas at the six col-
leges. Students were eligible if they were aged 16e24 years and
had ever had sexual intercourse. The participant information
leaﬂet and consent form provided information about STIs and the
study design (please see Supplementary Material). Participants
provided written informed consent. They were asked to complete
questionnaires (see Table 1 and Supplementary material), and to
provide samples (for research purposes only) in the nearest
washroom (urines for males, self-collected vaginal swabs for fe-
males) [15]. These samples were stored at e80C and tested blind
at St George's hospital after seven months using the Cobas 4800
CT/NG system (Roche diagnostics) [7]. All participants were
warned of the risks of untreated C. trachomatis/N. gonorrhoeae
and that their baseline samples would not be tested for seven
months, and advised to get checked for STIs independently of the
study.
Randomization
After recruitment of all participants, the six colleges were
randomly allocated 1:1 into the intervention group (TnT) or controlgroup (no TnT; Fig. 1) by the trial statistician using a computer-
generated allocation sequence [15].
Intervention colleges: TnT at 1 and 4 months
One month and 4 months after recruitment (to ﬁt with college
Autumn and Spring terms), each of the three intervention col-
leges were visited on two consecutive days by the research team.
We advertised the visit on college websites and notice boards,
and texted/emailed participating students the day before the visit
and on both days inviting them to come for TnT. Attendees came
to a private room to collect a test kit. When they returned with a
sample, it was tested for C. trachomatis/N. gonorrhoeae immedi-
ately on-site in a pop-up laboratory in a classroom using a 90-min
test [15] (one test/participant). Negative results were texted to
participants. The research team's nurse health adviser telephoned
participants with positive results and met them in another pri-
vate room in college (same day whenever possible) for conﬁ-
dential treatment for C. trachomatis, partner notiﬁcation and/or
referral.
Control colleges: no TnT
Participants from the three control colleges received texts
1 month and 4 months after recruitment thanking them for being
in the study.
Outcome assessment at 7 months
All six collegeswere visited again on two consecutive days in the
summer term using the same methods as in TnT above, and par-
ticipants from both groups were invited to provide repeat ques-
tionnaires and samples for immediate testing. Same-day results
and treatment were provided for all attenders (but these were not
part of the TnT intervention). Non-attenders were followed up by
text/email and telephone questionnaire and asked to give an
address (e.g. home/work/college) if they were willing to provide a
postal sample for testing [15].
Honoraria
Participants received £5 in cash when they returned samples at
recruitment and £10 after providing samples at the 7-month
follow-up. Participants in intervention colleges did not receive
honoraria for attending for TnT at 1 month and 4 months, as in the
UK people are not usually paid for having an STI test.
Masking
Recruitment of colleges and participants was conducted blind to
group allocation. After the ﬁrst TnT intervention, participants and
researchers were no longer blinded.
Main outcome measures
The key values to inform feasibility, sample size, and timescales
of a deﬁnitive trial were
 recruitment rates
 TnT uptake in intervention participants at one and four-months
 follow-up rates at 7 months
 prevalence of C. trachomatis at baseline and 7 months
 time to receiving results and treatment (ﬁdelity of TnT)
 acceptability of TnT in intervention colleges from thematically-
analysed semi-structured interviews [16] with purposively
Table 1
Baseline characteristics of 509 Further Education college students allocated to
intervention and control arms of the Test and Treat C. trachomatis screening trial
Characteristic Intervention Control
(n ¼ 259) (n ¼ 250)
Male % (n) 49.8 (129) 44.4 (111)
Age median (IQR) 17.6
(16.8-18.6)
18.0
(17.3-18.9
Ethnicity % (n)
White 27.2 (70) 25.5 (63)
Black African/Black Caribbean/Black British 48.6 (125) 51.0 (126)
Asian/Asian British 5.1 (13) 6.1 (15)
Mixed/multiple ethnicities 15.2 (39) 12.6 (31)
Other ethnic group 3.9 (10) 4.9 (12)
Sexual Preference (females) % (n)
Sex with men only 86.8 (112) 89.9 (124)
Sex with women only 3.9 (5) 1.4 (2)
Sex with men and women 4.7 (6) 7.2 (10)
Prefer not to say 4.7 (6) 1.4(2)
Sexual Preference (males) % (n)
Sex with men only 3.9 (5) 2.7 (3)
Sex with women only 93.0 (120) 94.6 (105)
Sex with men and women 1.6 (2) 2.7 (3)
Prefer not to say 1.6 (2) 0.0 (0)
Age at ﬁrst sexual intercourse <16 years % (n) 44.8 (112) 47.3 (112)
Two or more partners in past 12 months % (n) 56.6 (145) 53.5 (130)
New sexual partner in past 6 months % (n) 55.5 (141) 51.4 (128)
Female contraception % (n)
Condoms 56.2 (73) 54.0 (75)
Pill 16.9 (22) 20.9 (29)
Implant/coil 15.4 (20) 17.3 (24)
None 20.0 (26) 15.1 (21)
Other 2.3 (3) 2.9 (4)
Condom use (male and female) % (n)
Always 36.2 (92) 36.0 (89)
Usually 17.7 (45) 21.1 (52)
Sometimes 31.1 (79) 26.3 (65)
Never 15.0 (38) 16.6 (41)
Last STI check % (n)
Never 46.1 (118) 41.9 (103)
In the past 6 months 36.7 (94) 35.8 (88)
More than 6 months ago 17.2 (44) 22.4 (55)
STI history ever % (n)
C. trachomatis 7.5 (19) 8.9 (22)
N. gonorrhoeae 5.7 (14) 4.2 (10)
Other STI 0.9 (2) 1.3 (3)
NSU 0.4 (1) 1.3 (3)
Pelvic Inﬂammatory Disease in
past 6 months (females only)
2.4 (3) 2.2 (3)
Symptoms in past 6 months (female) % (n)
Bleeding between periods 17.5 (21) 15.9 (21)
Abnormal vaginal discharge 11.9 (14) 14.8 (19)
Pelvic discomfort other
than normal period pain
7.0 (8) 13.2 (17)
Pain during sex 17.4 (20) 17.3 (23)
Symptoms in past 6 months (male) % (n)
Pain/burning when urinating 6.5 (8) 7.4 (8)
Discharge from your penis 2.4 (3) 1.9 (2)
Pain or discomfort in testicles 6.5 (8) 4.7 (5)
Pain/burning from back passage 2.5 (3) 1.9 (2)
Smokes cigarettes % (n) 34.3 (87) 32.4 (81)
Alcohol-reports was
drunk in past month % (n)
48.4 (123) 48.3 (119)
Visited GP in past 6 months % (n) 59.1 (149) 61.6 (151)
Visited Sexual health clinic in
past 6 months % (n)
31.2 (79) 29.6 (72)
Visited Walk-in clinic in past 6 months % (n) 29.1 (73) 31.6 (77)
Visited A&E/hospital in past 6 months % (n) 36.0 (91) 31.8 (78)
Attended healthcare facility for sexual
health reasons in the past 6 months % (n)
36.9 (94) 35.4 (87)
C. trachomatis at baselinea % (n) 7.1 (18) 5.2 (13)
N. gonorrhoeae at baselinea % (n) 1.2 (3) 0 (0)
Similar numbers of students were recruited from each college (intervention colleges
n¼ 84, 85, 90; total 259: control colleges n¼ 83, 78, 89; total 250). NSU, non-speciﬁc
urethritis; GP, general practitioner; A&E, Accident and Emergency department.
a Baseline samples were stored and tested after 7 months.
P. Oakeshott et al. / Clinical Microbiology and Infection 25 (2019) 865e871 867sampled students (n ¼ 26 to ensure a range of ages, genders and
ethnicities) who did/did not attend for TnT (to be published
elsewhere).
Sample size and statistical analysis
Sixty to 100 subjects are sufﬁcient to estimate an event ratewith
acceptable precision (i.e. sufﬁciently narrow conﬁdence intervals)
in a feasibility study [15,17]. As previously described [18], assuming
a 30% recruitment rate [13], we aimed to approach 1600 students to
recruit 480 overall (80 per college across six colleges).
Progression criteria to a deﬁnitive trial were TnT uptake 60%
[13] at 1 and 4months and TnT being acceptable to participants [16]
(intervention colleges only), and follow-up rate 70% [12] at
7 months (all colleges).
Since this was a feasibility study, no signiﬁcance testing was
performed [19]. Descriptive statistics are presented, with corre-
sponding exact 95% conﬁdence intervals. Analyses [18] were per-
formed in Stata version 14. As our analysis was of feasibility
outcomes, the sample size and analysis were not adjusted for
clustering.
Ethics approval and consent to participate
Bromley REC reviewed the study (reference 15/LO/1929).
Parental consent for 16e18 year olds was not required.
Results
Recruitment
Over 3 weeks in September/October 2016, we recruited 509
participants from six colleges (range 78e90 per college). We were
unable to obtain information on all non-participants, but
completed recruitment forms for 180 non-participants suggested
that 67% (121/180) were ineligible due to never having had sexual
intercourse, 14% (25/180) were ineligible for other reasons (e.g. not
aged 16e24), and 19% (34/180) were eligible but declined.
Participants' median age was 17.9 years and 90% (458) were
teenagers (aged 16e19 years). Participants described their ethnicity
as black (50%), white (26%), or other ethnic groups (24%). Approx-
imately half (47%, 240) were male, including 117 (23%) black male
teenagers. Over half (55%) reported two or more sexual partners in
the previous year, and a third (36%) said they had been tested for
STIs in the past 6 months. Eligible non-participants (n ¼ 34) were
similar to participants in age and ethnicity (median age 17, IQR
17e19; 53% black ethnicity), but a slightly higher proportion (67%)
were male. Table 1 shows baseline characteristics of participants
from intervention and control colleges.
TnT uptake at 1 month and 4 months in intervention colleges
Thirteen percent (33/259; 95% CI 8.9e17.4%) of intervention
participants attended for on-site rapid tests and provided samples
at 1 month and 10% (26/259; 95% CI 6.7e14.4%) at 4 months,
despite implementing changes suggested by students and staff to
increase uptake. These included brief information for tutors to
give to their tutorial groups, educational posters (please see
Supplementary Material), user-friendly texts, and free condoms.
Five students provided samples at both 1 and 4 months. Of 59
tests, three (5.1%, 1.1e14.2) were positive for C. trachomatis. Two
students with C. trachomatis only were treated on site (one same
day, one next day), and one with dual C. trachomatis/
N. gonorrhoeae infection was referred for treatment as per
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who did/did not provide samples for TnT were broadly similar,
although more TnT attenders than non-attenders had a history of
C. trachomatis (13% versus 6%), and more were men who had sex
with men (MSM, 15% versus 3%).
Follow-up
Overall follow-up at 7 months was 62% (317/509; 95% CI
58e67%) for questionnaires and 52% (264/509; 95% CI 47e56%)Number of c
n = 6
Number of students
provided samples
n = 509
TnT
3 colleges
259 students
1 month TnT*
33 students tested
4 months TnT*
26 students tested
Reasons no data at 7 months  
follow up (n=108)
- Lost to follow-up (n=84)
- Declined to provide 
sample/quesƟonnaire 
(n=8)
- Withdrawn/ hung up 
(n=9)
- Agreed to provide sample 
but didn’t (n=7)
7 months follow up
Total – 151 students
Samples –119 students**
QuesƟonnaire data - 150 students** *
- College quesƟonnaire (n=98)
- Email quesƟonnaire (n=26)
- Telephone quesƟonnaire (n=13)
- Limited telephone quesƟonnaire (n=13****)
Re
fo
*Five parƟcipants provided samples at both one and four
** Two addiƟonal samples from each arm did not give a v
*** One parƟcipant only returned a sample but did not co
**** Limited quesƟonnaire data were collected while info
posiƟve baseline test for five and two individuals in the in
respecƟvely.
Fig. 1. Consort ﬂow diagram for Test n Treat/TnT cluster randomised feasibilifor samples. (A further four participants provided invalid sam-
ples: three with no human DNA, one delayed postal sample.)
Almost half the participants (46%, 232/509) completed follow-up
questionnaires at college, a further 9% (46/509) subsequently
completed an online questionnaire and 8% (39/509) a brief
telephone questionnaire. These showed 29% of intervention
participants and 25% of control participants reported STI testing
outside the trial. (Other study-related behaviours reported at
follow-up are shown in Table 3). Valid samples for testing were
provided at college by 229 (45%) participants and later by postolleges 
 recruited and 
at baseline
Control – no TnT
3 colleges
250 students
7 months follow up
Total – 167 students
Samples – 145 students**
QuesƟonnaire data - 167 students 
- College quesƟonnaire (n=134)
- Email quesƟonnaire (n=20)
- Telephone quesƟonnaire (n=7)
- Limited telephone quesƟonnaire (n=6****)
asons no data at 7 months 
llow up (n=83)
- Lost to follow-up (n=64)
- Declined to provide 
sample/quesƟonnaire (n=2)
- Withdrawn/ hung up (n=9)
- Agreed to provide sample 
but didn’t (n=8)
 months.
alid result 
mplete a quesƟonnaire 
rming parƟcipants by telephone of a 
tervenƟon and control groups 
ty trial of rapid chlamydia tests and on-site treatment in six FE colleges.
Table 2
Baseline characteristics of 259 intervention students who either attended TnT and
provided samples, or did not attend TnT at 1 month and/or 4 months
Baseline characteristic Attended TnT Did not
attend TnT
(n ¼ 54a) (n ¼ 205)
Male % (n) 48.1 (26) 50.2 (103)
Age median (IQR) 17.4
(16.7 to 18.7)
17.7
(16.8 to 18.5)
Ethnicity % (n)
White 28.8 (15) 26.8 (55)
Black African/Black
Caribbean/Black British
51.9 (27) 47.8 (98)
Asian/Asian British 1.9 (1) 5.9 (12)
Mixed/multiple ethnicities 13.5 (7) 15.6 (32)
Other ethnic group 3.8 (2) 3.9 (8)
Sexual Preference (females) % (n)
Sex with men only 100.0 (27) 83.3 (85)
Sex with women only 0.0 (0) 4.9 (5)
Sex with men and women 0.0 (0) 5.9 (6)
Prefer not to say 0.0(0) 5.9 (6)
Sexual Preference (males) % (n)
Sex with men only 7.7 (2) 2.9 (3)
Sex with women only 84.6 (22) 95.1 (98)
Sex with men and women 7.7 (2) 0.0 (0)
Prefer not to say 0.0 (0) 1.9 (2)
Age ﬁrst sex <16 years % (n) 44.2 (23) 44.9 (89)
Two or more partners in
past 12 months % (n)
50.9 (27) 58.1 (118)
New partner in past 6 months % (n) 50.9 (27) 56.7 (114)
Female contraception % (n)
Condoms 67.9 (19) 52.9 (54)
Pill 14.3 (4) 17.6 (18)
Implant/coil 14.3 (4) 15.7 (16)
None 14.3 (4) 21.6 (22)
Other 7.1 (2) 1.0 (1)
Condom use (male and female) % (n)
Always 41.5 (22) 34.8 (70)
Usually 17.0 (9) 17.9 (36)
Sometimes 30.2 (16) 31.3 (63)
Never 11.3 (6) 15.9 (32)
Last STI check % (n)
Never 45.3 (24) 46.3 (94)
In the past 6 months 35.8 (19) 36.9 (75)
More than 6 months ago 18.9 (10) 16.7 (34)
STI ever % (n)
C. trachomatis 13.2 (7) 6.0 (12)
N. gonorrhoeae 8.2 (4) 5.1 (10)
Other STI 0.0 (0) 1.0 (2)
NSU 0.0 (0) 0.5 (1)
Pelvic Inﬂammatory Disease
in past 6 months
11.1 (3) 0.0 (0)
Symptoms in past 6 months (female) % (n)
Bleeding between periods 25.0 (6) 15.6 (15)
Abnormal vaginal discharge 12.5 (3) 11.7 (11)
Pelvic discomfort other
than normal period pain
8.7 (2) 6.6 (6)
Pain during sex 14.3 (3) 18.1 (17)
Symptoms in past 6 months (male) % (n)
Pain/burning when urinating 4.0 (1) 7.1 (7)
Discharge from your penis 0.0 (0) 3.1 (3)
Pain or discomfort in testicles 8.0 (2) 6.1 (6)
Pain/burning from back passage 4.2 (1) 2.1 (2)
Smokes cigarettes % (n) 22.6 (12) 37.3 (75)
Alcohol-reports was drunk
in past month % (n)
43.2 (22) 49.8 (101)
Visited GP in past 6 months % (n) 53.8 (28) 60.5 (121)
Visited sexual health clinic in
past 6 months % (n)
39.2 (20) 29.2 (59)
Visited Walk-in clinic in past 6 months % (n) 30.0 (15) 28.9 (58)
Visited A&E/hospital in past 6 months % (n) 27.5 (14) 38.1 (77)
Attended healthcare facility for sexual
health reasons in past 6 months % (n)
46.2 (24) 34.5 (70)
C. trachomatis at baseline % (n) 3.7 (2) 8.0 (16)
N. gonorrhoeae at baseline % (n) 0.0 (0) 1.5 (3)
a Five participants attended at both one and four months.
Table 3
Reported behaviours during the study from 7-month follow-up questionnaires
Follow-up characteristics, % (n) Intervention Control
(n ¼ 150) (n ¼ 167)
Follow up method
College questionnaire 65.3 (98) 80.2 (134)
E-mail questionnaire 17.3 (26) 12.0 (20)
Telephone questionnaire 8.7 (13) 4.2 (7)
Limited telephone questionnaire 8.7 (13) 3.6 (6)
Have they been tested for chlamydia or gonorrhoea outside the study?
Yes 29.3 (44) 25.1 (42)
Where did they get tested?
GP 21.2 (7) 12.8 (5)
Sexual health clinic 33.3 (11) 56.4 (22)
Walk in clinic 9.1 (3) 5.1 (2)
Hospital 3.0 (1) 2.6 (1)
College 27.3 (9) 17.9 (7)
Other 6.1 (2) 5.1 (2)
Smoking (cigarettes per day)
None 69.7 (83) 65.5 (91)
1e10 25.2 (30) 30.9 (43)
More than 10 5.0 (6) 3.6 (5)
Vape (smoke electronic cigarettes)
No 85.9 (110) 84.7 (133)
Yes 6.3 (8) 4.5 (7)
Occasionally 7.8 (10) 10.8 (17)
Alcohol (number of times drunk in past month)
None 61.7 (79) 51.3 (80)
1e4 times 28.9 (37) 41.0 (64)
5 or more 9.4 (12) 7.7 (12)
Visited GP in past 6 months 56.4 (75) 49.4 (79)
Visited GUM clinic in past 6 months 22.1 (29) 25.8 (41)
Visited Walk-in clinic in past 6 months 22.1 (29) 25.6 (40)
Visited A&E/hospital in past 6 months 28.8 (38) 23.1 (37)
Attended healthcare facility for
sexual health reasons
15.1 (39) 17.2 (43)
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acteristics of those who did/did not provide samples at 7 months
follow-up.
Prevalence of C. trachomatis/N. gonorrhoeae at baseline and
7 months
Prevalences of C. trachomatis and N. gonorrhoeae respectively
were 6.2% (31/503; 4.2e8.6%) and 0.6% (3/503, 0.1e1.7%) at
baseline (six samples were discarded as mislabelled). Prevalences
at follow-up were C. trachomatis 6.1% (16/264, 3.5e9.7%, including
15 C. trachomatis only positive samples (13 college, two postal)
and one dual infection); and N. gonorrhoeae 1.1% (3/264, 0.2e3.3%,
including the dual infection). The prevalence of C. trachomatis in
males and females was 6.8% (16/236) and 5.6% (15/267) at base-
line; and 3.2% (4/125) and 8.6% (12/139) at follow-up. The three
cases of N. gonorrhoeae at baseline were in males, the three at
follow-up were in females. Prevalence of C. trachomatis in those
tested at each college ranged from 1.3e8.4% at baseline (intraclass
correlation coefﬁcient 0.002), and 2.4e10.4% at follow-up
(Table S2).
Time to results and treatment
For samples provided at college at 1, 4, and 7 months, most
results (90%, 259/288) were received by participants the same day.
Median time to being informed of a negative result (n ¼ 267) was
2.1 h (IQR 1.8e2.7 h, range 1.5 h to 23 days due to an administrative
error). For the 15 cases of C. trachomatis only which were diagnosed
in college (2 þ 13 at months 1/4, and 7), ten were treated on-site
(six same day, four next day), three were conﬁrmed treated later
P. Oakeshott et al. / Clinical Microbiology and Infection 25 (2019) 865e871870elsewhere (timing unclear for one), and two were not conﬁrmed
treated. Median time to conﬁrmed treatment for C. trachomatis only
(n ¼ 12) was 14.6 h (IQR 2.4e26.3 h, range 1.7 h to 27 days due to a
problem with a mobile number).
Acceptability
Semi-structured interviews in JanuaryeMarch 2017 with 13
students who attended for TnT and 13 who did not suggested that
low uptake of TnT was associated with not feeling at risk, percep-
tions of stigma, and lack of knowledge about STIs. However, all
were positive about TnT: ‘I think the service you provide is actually
very good because like most kids I think they would be too shy to
like go out and get checked….’ (male, 16, black, TnT non-attender).
Comments from attenders included: ‘amazing’, ‘educational’,
‘friendly’, ‘helpful’.
Discussion
Principal ﬁndings
Rapid recruitment of sexually active teenagers was possible
with £5 honoraria. However, despite high rates of C. trachomatis at
both baseline and follow-up, the proportion of participants
attending for non-incentivized college-based TnT was low: 13% at
1 month and 10% at 4 months. Although predetermined progres-
sion criteria for a deﬁnitive trial were not met, ﬁndings provide
important insights for designing future studies and for public
health policy.
Strengths and weaknesses
This was a unique study in a group of often socio-
economically deprived, ethnically diverse, inner-city teenagers.
It included >100 black, sexually experienced teenage males, a
group not often included in European STI research studies [4,7].
Participants had high rates of undiagnosed STIs including six
participants with heterosexual N. gonorrhoeae, all from black and
minority ethnic groups. It is also the ﬁrst randomized study of
rapid tests with on-site C. trachomatis treatment in FE colleges. It
was a pragmatic study in a relevant setting to reach sexually
active young people. Data on teenage lifestyles may inform
future studies.
There are limitations. Opportunistic recruitment meant it was
difﬁcult to calculate a recruitment rate. We could not use the
college population aged 16e24 (range approximately 500e3000
per college) as the denominator because assessment of eligibility
required information on sexual history. As in other studies [4,20]
we used self-reported data, which is subject to inaccurate recall.
However, reported history of C. trachomatis was similar to rates
in 16e24-year-old Londoners taking part in the population-
based National Surveys of Sexual Attitudes and Lifestyles (8.2%,
41/502 in our study versus 7.0%, 19/273 in Natsal-3 UK data
archive). Only two-thirds (10/15) of C. trachomatis only positives
diagnosed in college were treated on-site. A faster 30-min test
might have encouraged more students to wait for results [21],
but no such suitable test was available. Although all participants
diagnosed with infections were informed that their partners
needed treatment, we did not have partners' consent to conﬁrm
notiﬁcation. The study design meant TnT was only available to
those already recruited. This would not happen if TnT were
rolled out in routine practice. Follow-up rates were lower than
the 81% in the recent ‘Safetxt’ pilot trial [22], but most of their
participants were white, and/or aged 20e24. Our ﬁndings may
not apply to such groups.Comparison with other studies
Rates of testing were lower than (54e60%) expected from our FE
college-based pilot work [13,16,23], but similar to that in
16e29 year olds in a large Dutch register-based C. trachomatis
screening trial: 16% in the ﬁrst round decreasing to 11% in the
second [8] with no substantial decrease in STI positivity rates.
Another study from a Scottish FE college found 17% C. trachomatis
testing uptake in teenagers [24], suggesting this is a challenging
group to engage. By contrast, in the French Chlamyweb study [7]
uptake by 18e24 year olds of an online offer of home-based
C. trachomatis testing was 24% in males and 34% in females with
positivity rates of 4.4% and 8.3% respectively. Similarly, in ‘SH24’,
internet accessed postal testing almost doubled uptake of STI
testing [20]. However, most participants were white and/or aged
20e30 years. As in other studies [7,16] many of our teenage par-
ticipants did not want a test kit posted to their home. The high
C. trachomatis positivity rates in Chlamyweb and our study were
similar to those observed in STI clinics [7] and roughly double the
rates in population-based studies in sexually experienced males
and females aged 16e24 in England [5] (2.3% and 3.1%) and the USA
[25] (1.7% and 3.2% respectively). Finally, there were more MSM
among TnTattenders than non-attenders. MSMmay bemore aware
of STI prevention [20].
Themedian time fromdiagnosis to treatment (within 1 day) was
similar to a recent feasibility study of online C. trachomatis man-
agement via an eSexual health clinic [26]. Overall rates of
conﬁrmed treatment for C. trachomatis (87%, 13/15) were similar to
ChlamywebII [7] (87%, 58/67) and 2014 English National Chlamydia
Screening Programme results (91% within 6 weeks of test date
[27]). Participants' lack of knowledge about STIs was in line with
community-based studies from the USA, Europe, and Australia
[16,24,28e30]. Sex education is optional in English state secondary
schools.
Conclusions and perspectives
The low uptake of TnT despite high rates of STIs suggests that a
deﬁnitive trial of TnT using this design is not feasible in FE colleges.
It highlights both the difﬁculties of designing studies to reach
sexually active young people, and the crucial need for better sex
and relationships education [2]. This should include ‘normalization’
of STI testing [20] making it routine/acceptable to get checked.
However, accessing testing is often problematic [1]. In the UK,
funding cuts have closed many sexual health clinics, and relying on
internet postal testing may disadvantage vulnerable teenagers [20].
Future trials might evaluate college-wide, multicomponent, com-
bined Education/TnT interventions. This could include lessons of-
fering user-friendly information on STIs, free condoms, and postal
test kits perhaps followed by pop-up clinics offering conﬁdential,
on-site TnT.
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